Revive Therapeutics trades on the Canadian Venture Exchange (CVE) under the ticker symbol "RVV." How do I buy shares of Revive Therapeutics? Shares of RVV and other Canadian stocks can be purchased through an online brokerage account.
What happened to the revive Therapeutics Ltd stock price?
The Revive Therapeutics Ltd stock price fell by -3.34% on the last day (Friday, 14th Jan 2022) from $0.25 to $0.24. During the day the stock fluctuated 13.40% from a day low at $0.24 to a day high of $0.27.
What is revive Therapeutics'product pipeline?
Its product pipeline also includes REV-004, a bucillamine for the treatment of cystinurial. The company has a research and development supply and collaboration agreement with WeedMD Inc. Revive Therapeutics Ltd. was incorporated in 2012 and is headquartered in Vaughan, Canada.
Is revive Therapeutics'P/E ratio overvalued?
The P/E ratio of Revive Therapeutics is -3.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Revive Therapeutics has a P/B Ratio of 4.21. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.
Where is revive Therapeutics located?
Revive Therapeutics is headquartered at 5 Director Crt Suite 105, WOODBRIDGE, ON L4L 4S5, Canada. How can I contact Revive Therapeutics?
See more
Is revive a good stock to buy?
Revive Therapeutics is a potential penny stock. Although Revive Therapeutics may be in fact a good instrument to invest, many penny otc stocks are speculative in nature and are subject to artificial price hype.
Will Rvvtf stock go up?
Based on our forecasts, a long-term increase is expected, the "RVVTF" stock price prognosis for 2027-06-16 is 0.7084 USD. With a 5-year investment, the revenue is expected to be around +144.26%. Your current $100 investment may be up to $244.26 in 2027.
What does revive therapeutics do?
Revive Therapeutics Advances Inflammatory Liver Disorders Programs for Autoimmune Hepatitis and Liver Transplantation.
Is RVV a good stock?
Revive Therapeutics Stock Price History Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and RVV.CX is experiencing selling pressure, which indicates risk of future bearish movement.
How has Revive Therapeutics' stock price performed in 2022?
Revive Therapeutics' stock was trading at C$0.08 at the beginning of 2022. Since then, RVV shares have increased by 0.0% and is now trading at C$0....
When is Revive Therapeutics' next earnings date?
Revive Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, October 24th 2022. View our earnings forecast for...
Who are Revive Therapeutics' key executives?
Revive Therapeutics' management team includes the following people: Mr. Craig Leon , Chairman & CEO (Age 51) Mr. Fabio Chianelli , Pres & Direc...
Who are some of Revive Therapeutics' key competitors?
Some companies that are related to Revive Therapeutics include Liberty Biopharma (LTY) , OptiBiotix Health (OPTI) , AorTech International (AOR)...
What other stocks do shareholders of Revive Therapeutics own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Revive Therapeutics investors own include Heat Biologics (...
What is Revive Therapeutics' stock symbol?
Revive Therapeutics trades on the Canadian Venture Exchange (CVE) under the ticker symbol "RVV."
How do I buy shares of Revive Therapeutics?
Shares of RVV and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian...
What is Revive Therapeutics' stock price today?
One share of RVV stock can currently be purchased for approximately C$0.08.
How much money does Revive Therapeutics make?
Revive Therapeutics (CVE:RVV) has a market capitalization of C$5.79 million.
About Revive Therapeutics
Revive Therapeutics Ltd. develops and commercializes cannabinoid-based products in Canada. The company develops REV-002, a bucillamine that has completed Phase II-A clinical studies for the treatment of acute gout flares. Its product pipeline also includes REV-004, a bucillamine for the treatment of cystinurial.
Headlines
NA Proactive news snapshot: CO2 GRO, Revive Therapeutics, Goldshore Resources, Else Nutrition, GR Silver Mining, Ketamine One UPDATE ...
Revive Therapeutics (CVE:RVV) Frequently Asked Questions
Revive Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, March 7th 2022. View our earnings forecast for Revive Therapeutics.
What is Revive Therapeutics Ltd?
(“Revive” or the “Company”) (CSE: RVV), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announces that its Annual and Special Meeting (the “Meeting”) scheduled to be held at 11:00 a.m. Eastern Daylight Time on April 12, 2021 will be adjourned to a future date. Due to the current provincial lockdown in response to the COVID-19 pandemic, the Meeting was to be held by way of conference call. Due to the high shareholder turnout and interest, the service provider contracted to arrange the conference call experienced technical difficulties with the bridge facilities. In order to ensure that all shareholders are able to attend and participate at the Meeting, the Company has decided to adjourn the Meeting in order to procure enhanced conference facilities. A subsequent press release will be disseminated with the updated call-in information. About Revive Therapeutics Ltd. Revive is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders, and it is prioritizing drug development efforts to take advantage of several regulatory incentives awarded by the FDA such as Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease designations. Currently, the Company is exploring the use of Bucillamine for the potential treatment of infectious diseases, with an initial focus on COVID-19. With its recent acquisition of Psilocin Pharma Corp., Revive is advancing the development of Psilocybin-based therapeutics in various diseases and disorders. Revive’s cannabinoid pharmaceutical portfolio focuses on rare inflammatory diseases and the company was granted FDA orphan drug status designation for the use of Cannabidiol to treat autoimmune hepatitis (liver disease) and to treat ischemia and reperfusion injury from organ transplantation. For more information, visit www.ReviveThera.com. For more information please contact: Michael FrankChief Executive OfficerRevive Therapeutics Ltd. Tel:1 888 901 0036Email:[email protected] Website:www.revivethera.com Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.
Is TBI a subset of TBI?
There are no FDA approved treatments for cognitive impairments due to TBI. Moderate to severe TBI is a subset of TBI and can lead to a physical, cognitive, emotional, and behavioral changes over the course of a person’s life. These changes may affect a person’s ability to function in their everyday life.
Does psilocybin help with TBI?
Psilocybin has the potential with its neuroreparative effect to improve loss of cognitive function after TBI lessening disability. The clinical effect of psilocybin appears to be related to its attenuation of traumatically-induced glutamate excitotoxicity during the early post-injury period.
Signals & Forecast
A buy signal was issued from a pivot bottom point on Tuesday, February 15, 2022, and so far it has risen 5.00%. Further rise is indicated until a new top pivot has been found. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD).
Support, Risk & Stop-loss
Revive Therapeutics Ltd finds support from accumulated volume at $0.20 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.
Is Revive Therapeutics Ltd stock A Buy?
Revive Therapeutics Ltd holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock.
Golden Star Signal
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
What is Revive Therapeutics?
Revive Therapeutics Ltd is focused on the research, development, and commercialization of novel psychedelic and cannabinoid-based life sciences products and drug repurposing for infectious diseases. The firm's technology is being developed to fill the medical needs for diseases and disorders such as pain, inflammation, and wound care.
What is transparency in investing?
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
What is Stock Sentiment?
Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends.
What's Happening With RVVTF Stock Today?
Revive Therapeutics Ltd (RVVTF) stock is trading at $0.39 as of 9:43 AM on Thursday, Sep 9, a rise of $0.02, or 6.31% from the previous closing price of $0.37. The stock has traded between $0.36 and $0.39 so far today. Volume today is below average. So far 178,065 shares have traded compared to average volume of 1,176,014 shares.
More About Revive Therapeutics Ltd
Revive Therapeutics Ltd is focused on the research, development, and commercialization of novel psychedelic and cannabinoid-based life sciences products and drug repurposing for infectious diseases. The firm's technology is being developed to fill the medical needs for diseases and disorders such as pain, inflammation, and wound care.
News More News
GAINERS: Revive Therapeutics (OTC: RVVTF) shares closed up 2.51% at $0.22 LOSERS: Mind Medicine (NASDAQ: MNMD) shares closed down 8.09% at $1.25 Cybin (AMEX:CYBN) shares closed down 6.25% at $1.05 ATAI Life SciencesGAINERS:
Mind Medicine, Cybin Among Top Psychedelic Movers Of Today
GAINERS: Revive Therapeutics (OTC: RVVTF) shares closed up 2.51% at $0.22 LOSERS: Mind Medicine (NASDAQ: MNMD) shares closed down 8.09% at $1.25 Cybin (AMEX:CYBN) shares closed down 6.25% at $1.05 ATAI Life SciencesGAINERS:
